Skip to main content

Advertisement

SpringerLink
Log in

Dysregulation of MicroRNA-34a Expression in Colorectal Cancer Inhibits the Phosphorylation of FAK Via VEGF

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

MicroRNAs (miRs) are small non-coding RNAs that play important roles in cancer development where they can act as oncogenes or as tumor-suppressors. MiR-34a is a tumor suppressor that is frequently downregulated in a number of tumor types. However, little is known about the role of miR-34a in colorectal cancer (CRC).

Aim

This study aims to show the dysregulation of miR-34a in CRC and to characterize the function and mechanism of miR-34a in CRC cell lines.

Methods

The expression of miR-34a was detected using real-time PCR on CRC tissues and adjacent non-tumorous tissues. The ELISA was used to assess vascular endothelial growth factor (VEGF). The focal adhesion kinase (FAK) and phosphorylated FAK Y397 (pY397FAK) were measured by Western blot. The functions of miR-34a in vivo were measured by migration, invasion, CCK-8 assay and flow cytometry.

Results

MiR-34a was significantly downregulated and pY397FAK was upregulated in CRC cancer tissues. It plays an important role in inhibiting migration and invasion and in increasing apoptosis of CRC cells. Bioinformatic analysis suggested that VEGF may be a target of miR-34a, and this hypothesis was proved by ELISA and RT-PCR. The level of pY397FAK that could be activated by VEGF was downregulated in miR-34a overexpression CRC cell lines. The phosphorylation of FAK at 397 sites in miR-34a-stable cell lines was completely rescued by extra VEGF treatment.

Conclusion

MiR-34a is frequently downregulated in CRC and modulates the phosphorylation of FAK by negatively regulating VEGF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

    Article  PubMed  Google Scholar 

  2. Pellegrino L, Jacob J, Roca-Alonso L, Krell J, Castellano L, et al. Altered expression of the miRNA processing endoribonuclease Dicer has prognostic significance in human cancers. Expert Rev Anticancer Ther. 2013;13:21–27.

    Article  PubMed  CAS  Google Scholar 

  3. Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18:282–289.

    Article  PubMed  CAS  Google Scholar 

  4. Akbari Moqadam F, Pieters R, den Boer ML. The hunting of targets: challenge in miRNA research. Leukemia. 2013;27:16–23.

    Article  PubMed  CAS  Google Scholar 

  5. Pagliuca A, Valvo C, Fabrizi E, di Martino S, Biffoni M, et al. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene. 2013;32:4806–4813.

    Google Scholar 

  6. Takahashi M, Sung B, Shen Y, Hur K, Link A, et al. Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family. Carcinogenesis. 2012;33:2441–2449.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  7. de Krijger I, Mekenkamp LJ, Punt CJ, Nagtegaal ID. MicroRNAs in colorectal cancer metastasis. J Pathol. 2011;224:438–447.

    Article  PubMed  CAS  Google Scholar 

  8. Stratmann J, Wang CJ, Gnosa S, Wallin A, Hinselwood D, et al. Dicer and miRNA in relation to clinicopathological variables in colorectal cancer patients. BMC Cancer. 2011;11:345.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  9. Bensen JT, Tse CK, Nyante SJ, Barnholtz-Sloan JS, Cole SR, et al. Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the Carolina Breast Cancer Study. Cancer Causes Control. 2013;24:1099–1109.

    Google Scholar 

  10. Bandi N, Vassella E. miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol Cancer. 2011;10:55.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  11. Xu X, Fan Z, Kang L, Han J, Jiang C, et al. Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest. 2013;123:630–645.

    Google Scholar 

  12. Yue X, Wang P, Xu J, Zhu Y, Sun G, et al. MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A. Oncol Rep. 2012;27:1200–1206.

    PubMed Central  PubMed  CAS  Google Scholar 

  13. Volkomorov V, Grigoryeva E, Krasnov G, Litviakov N, Tsyganov M, et al. Search for potential gastric cancer markers using miRNA databases and gene expression analysis. Exp Oncol. 2013;35:2–7.

    PubMed  CAS  Google Scholar 

  14. Ji X, Wang Z, Geamanu A, Goja A, Sarkar FH, et al. Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in nonsmall cell lung cancer cells. Int J Cancer. 2012;131:2668–2677.

    Article  PubMed  CAS  Google Scholar 

  15. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun. 2008;377:114–119.

    Article  PubMed  CAS  Google Scholar 

  16. Duan W, Xu Y, Dong Y, Cao L, Tong J, et al. Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway. J Radiat Res. 2013;54:611–619.

    Google Scholar 

  17. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26:745–752.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  18. Zhao H, Ma B, Wang Y, Han T, Zheng L, et al. miR-34a inhibits the metastasis of osteosarcoma cells by repressing the expression of CD44. Oncol Rep. 2013;29:1027–1036.

    PubMed  CAS  Google Scholar 

  19. Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S, et al. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat. 2011;130:663–679.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  20. Gallardo E, Navarro A, Vinolas N, Marrades RM, Diaz T, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009;30:1903–1909.

    Article  PubMed  CAS  Google Scholar 

  21. Nalls D, Tang SN, Rodova M, Srivastava RK, Shankar S. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One. 2011;6:e24099.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  22. Roy S, Levi E, Majumdar AP, Sarkar FH. Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol. 2012;5:58.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  23. Cho SG, Yi Z, Pang X, Yi T, Wang Y, et al. Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation. Cancer Res. 2009;69:7062–7070.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  24. Chen XL, Nam JO, Jean C, Lawson C, Walsh CT, et al. VEGF-induced vascular permeability is mediated by FAK. Dev Cell. 2012;22:146–157.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  25. Schlaepfer DD, Hunter T. Signal transduction from the extracellular matrix—a role for the focal adhesion protein–tyrosine kinase FAK. Cell Struct Funct. 1996;21:445–450.

    Article  PubMed  CAS  Google Scholar 

  26. Pang X, Zhang L, Lai L, Chen J, Wu Y, et al. 1′-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway. Carcinogenesis. 2011;32:904–912.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  27. He K, Cui B, Li G, et al. The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC). Onco Targets Ther. 2012;5:59–65.

    PubMed Central  PubMed  CAS  Google Scholar 

  28. Sun F, Fu H, Liu Q, Tie Y, Zhu J, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 2008;582:1564–1568.

    Article  PubMed  CAS  Google Scholar 

  29. Hashimi ST, Fulcher JA, Chang MH, Gov L, Wang S, et al. MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation. Blood. 2009;114:404–414.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  30. Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, et al. TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012;22:291–303.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  31. Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, et al. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene. 2011;30:2888–2899.

    Article  PubMed  CAS  Google Scholar 

  32. Gilmore AP, Romer LH. Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. Mol Biol Cell. 1996;7:1209–1224.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by grants-in-aid for Special-Term Professor Scientific Research from the Educational Department of Liaoning Province, China (Liaocai Zhijiao no. 2012-512). All sources of financial support during the last 2 years are acknowledged.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of General Surgery, Gastrointestinal Surgery, The First Hospital, China Medical University, Shenyang, 110001, China

    Danhua Zhang, Jianping Zhou & Ming Dong

Authors
  1. Danhua Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jianping Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ming Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ming Dong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, D., Zhou, J. & Dong, M. Dysregulation of MicroRNA-34a Expression in Colorectal Cancer Inhibits the Phosphorylation of FAK Via VEGF. Dig Dis Sci 59, 958–967 (2014). https://doi.org/10.1007/s10620-013-2983-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-013-2983-4

Keywords

Search

Navigation